The MACS GMP PepTivator PRAME is a is a peptide pool that consists mainly of 15-mer peptides. It has been developed for efficient in vitro stimulation and subsequent isolation of PRAME-specific CD4
+
and CD8
+
T cells.

Specifications for
MACS
®
GMP PepTivator
®
PRAME

Overview

The MACS GMP PepTivator PRAME is a is a peptide pool that consists mainly of 15-mer peptides. It has been developed for efficient in vitro stimulation and subsequent isolation of PRAME-specific CD4
+
and CD8
+
T cells.

Detailed product information

Background information

PepTivator
®
PRAME is a pool of lyophilized peptides, consisting mainly of 15-mer sequences with 11 amino acids overlap, covering the complete sequence of the preferentially expressed antigen of melanoma (PRAME) (UniProt ID: P78395).
In vitro stimulation of antigen-specific T cells with PepTivator Peptide Pools causes the secretion of effector cytokines and the up-regulation of activation markers, which then allow the detection and isolation of antigen-specific T cells.

Applications

MACS GMP PepTivator PRAME can be used for a variety of applications, for example, in vitro stimulation of PRAME-specific CD4
+
and CD8
+
T cells for the enrichment of IFN‑gamma–secreting T cells using the CliniMACS
®
Cytokine Capture System (IFN-γ).

Quality statement

MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.

Disclaimer

MACS GMP Products are for research use and
ex vivo
cell culture processing only, and are not intended for human
in vivo
applications. For regulatory status in the USA, please contact your local representative.

Resources for
MACS
®
GMP PepTivator
®
PRAME

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for
MACS
®
GMP PepTivator
®
PRAME

Publications

  1. Gérard, C. et al. (2015) A comprehensive preclinical model evaluating the recombinant PRAME antigen combined with the AS15 immunostimulant to fight against PRAME-expressing tumors. J. Immunother. 38(8): 311-320
  2. Pollack, S. M. et al. (2012) NYESO-1/LAGE-1s and PRAME are targets for antigen-specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One 7(2): e32165
  3. Spel, L. et al. (2015) Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma. Oncotarget. 6(34): 35770-35781

Related products for
MACS
®
GMP PepTivator
®
PRAME

4 products available